A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary…
Articles by Marisa Horak, MS
Scientists in China have developed a phosphodiesterase-5 (PDE5) inhibitor for pulmonary arterial hypertension (PAH) that reduced disease severity in…
Advocates worldwide are gearing up for World Pulmonary Hypertension Day on May 5, focusing this year on the critical…
Babies with bronchopulmonary dysplasia (BPD), a lung disorder that affects premature infants and can lead to pulmonary hypertension (PH),…
Children with pulmonary hypertension (PH) engage in fewer and shorter bouts of intense physical activity than their peers, according…
The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, Inhibikase Therapeutics’ experimental formulation…
Patients with interstitial lung diseases (ILDs) who require supplemental oxygen are more than three times as likely to experience…
Anumana‘s AI-enabled algorithm for the early detection of pulmonary hypertension (PH) has been cleared for use by the…
In a large clinical trial, treatment with Winrevair (sotatercept-csrk) significantly reduced pressure in the lungs’ blood…
A history of smoking was associated with worse survival outcomes in male patients with pulmonary arterial hypertension (PAH), according…
Winrevair (sotatercept-csrk), an injection therapy approved for adults with pulmonary arterial hypertension (PAH), is now covered by several…
Measuring levels of tiny pieces of genetic material in the blood, known as microRNAs, may help identify group 2…